Special Issue

Patient-Adapted Multidisciplinary Approaches in Gastrointestinal Tract Tumors

Message from the Guest Editors

Although gastrointestinal (GI) cancers are among the most common cancer types and represent a leading cause of cancer-related deaths worldwide, there is a clear need for more effective therapies. A huge amount of effort is being directed towards the development of more sensitive and specific molecular profiling, including blood-based biomarkers for real-time monitoring. Moreover, immunotherapy is being actively incorporated into the treatment of GI cancers. particularly with the use of ICIs in certain molecular subtypes. This approach has led to survival improvements in different tumor types, but the outcomes of genomically guided treatments in GI cancers remain undetermined. It is anticipated that additional aspects beyond genomic signatures should be considered to create combined models that better define individual patients' needs. Among them, adoptive cell therapy and gene therapy, therapeutic drug monitoring, radiomics or intratumoral microbiota will likely soon be integrated as components of precision medicine in GI cancer patients. In this Special Issue, we aim to provide an overview of some of these emerging strategies.

Guest Editors

Dr. Javier Rodriguez

Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona, 31008 Navarra, Spain

Dr. Diego Salas-Benito

Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, United States

Deadline for manuscript submissions

closed (20 June 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/131984

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com_

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

